These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 20598534

  • 1. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
    Brigance RP, Meng W, Fura A, Harrity T, Wang A, Zahler R, Kirby MS, Hamann LG.
    Bioorg Med Chem Lett; 2010 Aug 01; 20(15):4395-8. PubMed ID: 20598534
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Synthesis and Evaluation of Novel [1,2,4]Triazolo[5,1-c][1,2,4]-triazines and Pyrazolo[5,1-c][1,2,4]triazines as Potential Antidiabetic Agents.
    Rusinov VL, Sapozhnikova IM, Bliznik AM, Chupakhin ON, Charushin VN, Spasov AA, Vassiliev PM, Kuznetsova VA, Rashchenko AI, Babkov DA.
    Arch Pharm (Weinheim); 2017 May 01; 350(5):. PubMed ID: 28393419
    [Abstract] [Full Text] [Related]

  • 4. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
    Sharma M, Gupta M, Singh D, Kumar M, Kaur P.
    Chem Biol Drug Des; 2012 Dec 01; 80(6):918-28. PubMed ID: 22943413
    [Abstract] [Full Text] [Related]

  • 5. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J, Peng L, Zhang G, Lan X, Li C, Chen F, Zhou Y, Lin Z, Chen L, Dai R, Xu H, Yang L, Zhang X, Hu W.
    Eur J Med Chem; 2011 Jan 01; 46(1):71-6. PubMed ID: 21106276
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
    Zhang L, Su M, Li J, Ji X, Wang J, Li Z, Li J, Liu H.
    Chem Biol Drug Des; 2013 Feb 01; 81(2):198-207. PubMed ID: 22994702
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.
    Ji X, Su M, Wang J, Deng G, Deng S, Li Z, Tang C, Li J, Li J, Zhao L, Jiang H, Liu H.
    Eur J Med Chem; 2014 Mar 21; 75():111-22. PubMed ID: 24531224
    [Abstract] [Full Text] [Related]

  • 8. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
    Banno Y, Miyamoto Y, Sasaki M, Oi S, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Tsubotani S, Tani A, Funami M, Tawada M, Yamamoto Y, Aertgeerts K, Yano J, Maezaki H.
    Bioorg Med Chem; 2011 Aug 15; 19(16):4953-70. PubMed ID: 21764322
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
    Maezaki H, Banno Y, Miyamoto Y, Moritoh Y, Asakawa T, Kataoka O, Takeuchi K, Suzuki N, Ikedo K, Kosaka T, Sasaki M, Tsubotani S, Tani A, Funami M, Yamamoto Y, Tawada M, Aertgeerts K, Yano J, Oi S.
    Bioorg Med Chem; 2011 Aug 01; 19(15):4482-98. PubMed ID: 21741847
    [Abstract] [Full Text] [Related]

  • 11. Identification of dipeptidyl peptidase IV inhibitors: virtual screening, synthesis and biological evaluation.
    Xing J, Li Q, Zhang S, Liu H, Zhao L, Cheng H, Zhang Y, Zhou J, Zhang H.
    Chem Biol Drug Des; 2014 Sep 01; 84(3):364-77. PubMed ID: 24674599
    [Abstract] [Full Text] [Related]

  • 12. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
    Gupta RC, Chhipa L, Mandhare AB, Zambad SP, Chauthaiwale V, Nadkarni SS, Dutt C.
    Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5021-5. PubMed ID: 19643608
    [Abstract] [Full Text] [Related]

  • 13. A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening.
    Kawaguchi M, Okabe T, Terai T, Hanaoka K, Kojima H, Minegishi I, Nagano T.
    Chemistry; 2010 Dec 03; 16(45):13479-86. PubMed ID: 20938933
    [Abstract] [Full Text] [Related]

  • 14. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
    Ammirati MJ, Andrews KM, Boyer DD, Brodeur AM, Danley DE, Doran SD, Hulin B, Liu S, McPherson RK, Orena SJ, Parker JC, Polivkova J, Qiu X, Soglia CB, Treadway JL, VanVolkenburg MA, Wilder DC, Piotrowski DW.
    Bioorg Med Chem Lett; 2009 Apr 01; 19(7):1991-5. PubMed ID: 19275964
    [Abstract] [Full Text] [Related]

  • 15. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.
    Meng W, Brigance RP, Chao HJ, Fura A, Harrity T, Marcinkeviciene J, O'Connor SP, Tamura JK, Xie D, Zhang Y, Klei HE, Kish K, Weigelt CA, Turdi H, Wang A, Zahler R, Kirby MS, Hamann LG.
    J Med Chem; 2010 Aug 12; 53(15):5620-8. PubMed ID: 20684603
    [Abstract] [Full Text] [Related]

  • 16. Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Pei Z, Li X, von Geldern TW, Madar DJ, Longenecker K, Yong H, Lubben TH, Stewart KD, Zinker BA, Backes BJ, Judd AS, Mulhern M, Ballaron SJ, Stashko MA, Mika AK, Beno DW, Reinhart GA, Fryer RM, Preusser LC, Kempf-Grote AJ, Sham HL, Trevillyan JM.
    J Med Chem; 2006 Nov 02; 49(22):6439-42. PubMed ID: 17064063
    [Abstract] [Full Text] [Related]

  • 17. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG.
    J Med Chem; 2005 Jul 28; 48(15):5025-37. PubMed ID: 16033281
    [Abstract] [Full Text] [Related]

  • 18. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
    Wiedeman PE, Trevillyan JM.
    Curr Opin Investig Drugs; 2003 Apr 28; 4(4):412-20. PubMed ID: 12808880
    [Abstract] [Full Text] [Related]

  • 19. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE.
    J Med Chem; 2005 Jan 13; 48(1):141-51. PubMed ID: 15634008
    [Abstract] [Full Text] [Related]

  • 20. A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
    Donnelly R.
    Diabetes Obes Metab; 2007 Mar 13; 9(2):151-2. PubMed ID: 17300590
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.